This educational activity is designed for oncologists, hematologists, physicians, internists, and other health care providers, including oncology pharmacists and allied oncology healthcare providers interested in the management of a variety of malignancies.

Chair:
	Mohammad Jahanzeb, MD, FACP Lynn Cancer Institute Boca Raton, Florida
Faculty:
	Kathy Albain, MD Loyola University Chicago Maywood, Illinois	John S. Macdonald, MD Aptium Oncology Castine, Maine
	Tanios Bekaii-Saab, MD Ohio State University Columbus, Ohio	Ruben Mesa, MD University of Chicago Chicago, Illinois
	Ronald Bukowski, MD Cleveland Clinic Foundation Cleveland, Ohio	Vincent Miller, MD Memorial Sloan-Kettering Cancer Center New York, New York
	Harold Burstein, MD, PhD Dana-Farber Cancer Institute Boston, Massachusetts	Bruce Minsky, MD University of Chicago Chicago, Illinois
	W. Jarrard Goodwin, Jr, MD University of Miami Miami, Florida	Ruth O’Regan, MD Emory University Atlanta, Georgia
	Joseph Jacobson, MD North Shore Medical Center Salem, Massachusetts	Marshall Posner, MD Dana-Farber Cancer Institute Boston, Massachusetts
	Gregory Kalemkerian, MD University of Michigan Ann Arbor, Michigan	Eric Vallieres, MD, FRCSC Swedish Cancer Institute Seattle, Washington
	Hagop Kantarjian, MD M. D. Anderson Cancer Center Houston, Texas	Charles Vogel, MD, FACP Cancer Institute West Boca Raton, Florida
	Merrill Kies, MD M. D. Anderson Cancer Center Houston, Texas	Stan Winokur Winokur Consulting Group West Palm Beach, Florida

 

Moderators:
	Arnold Berliner, MD Lynn Cancer Institute - West Boca Raton, Florida	Alan Koletsky, MD The Center for Hematology Oncology Boca Raton, Florida
	Marla Dudak, MD West Boca Medical Center Boca Raton, Florida	Reshma Mahtani, DO Lynn Cancer Institute - West Boca Raton, Florida
	Michael Kasper, MD Boca Raton Community Hospital Boca Raton, Florida	Caio Max S. Rocha Lima, MD University of Miami Miami, Florida

Friday, April 3, 2009
7:00 AM	Registration and continental breakfast
8:00 AM	Welcome and introduction Mohammad Jahanzeb, MD, FACP
Session I: Keynote Lecture
8:05 AM	The ASCO QOPI project: Past, present and future Joseph Jacobson, MD
Session II: Breast Cancer Moderator: Marla Dudak, MD
8:45 AM	Smartest Oncologist Quiz
9:00 AM	Estimating risk of recurrence in ER+ patients Kathy Albain, MD
9:25 AM	Management of recurrent HER-2 amplified breast cancer following adjuvant trastuzumab Harold Burstein, MD, PhD
9:50 AM	Selecting adjuvant endocrine therapy for hormone receptor positive patients Ruth O'Regan, MD
10:15 AM	Emerging antiangiogenic strategies in breast cancer Charles Vogel, MD, FACP
10:40 AM	Break
Session III: Head and Neck Cancer Moderator: Reshma Mahtani, DO
11:05 AM	Smartest Oncologist Quiz
11:20 AM	Towards personalizing systemic approaches in head and neck cancer Marshall Posner, MD
11:45 AM	Debate: The role of surgery is becoming more limited      Pro: Merrill Kies, MD      Contra: W. Jarrard Goodwin, Jr, MD
12:40 PM	Lunch
Session IV: Lung Cancer Moderator: Michael Kasper, MD
1:40 PM	Smartest Oncologist Quiz
1:55 PM	Treatment based on histologic subtypes Vincent Miller, MD
2:25 PM	Targeting molecular subtypes Gregory Kalemkerian, MD
2:55 PM	Advances in the surgical management of NSCLC Eric Vallieres, MD, FRCSC
3:20 PM	Smartest Oncologist Quiz results
3:30 PM	Adjourn
Saturday, April 4, 2009
7:00 AM	Continental breakfast
8:00 AM	Introduction
Session V: Hepatocellular Carcinoma Moderator: Caio Max S. Rocha Lima, MD
8:05 AM	Smartest Oncologist Quiz
8:20 AM	Systemic therapy for hepatocellular carcinoma Tanios Bekaii-Saab, MD
Session VI: Colorectal Cancer Moderator: Caio Max S. Rocha Lima, MD
8:50 AM	Combined modality therapy for rectal carcinoma Bruce Minsky, MD
9:15 AM	Selecting the right chemotherapy with the optimal targeted agent in colorectal cancer John S. Macdonald, MD
9:40 AM	Break
Session VII: Renal Cell Carcinoma Moderator: Alan Koletsky, MD
10:00 AM	Smartest Oncologist Quiz
10:10 AM	Prioritizing and individualizing targeted agents for patients with RCC Ronald Bukowski, MD
Session VIII: Hematologic Malignancies Moderator: Alan Berliner, MD
10:35 AM	Smartest Oncologist Quiz
10:45 AM	Evolution of therapy in CML: Matching patients with appropriate options Hagop Kantarjian, MD
11:15 AM	MDS: What have we learned? Ruben Mesa, MD
11:45 AM	Smartest Oncologist Quiz results
11:55 AM	Closing remarks
12:00 PM	Adjourn

Upon successful completion of this educational activity, participants should be better able to:

• Describe a comprehensive approach to the state-of-the-art management of lung, breast, colorectal, head and neck cancers and hematologic malignancies, as well as renal cell and hepatocellular carcinomas
• Explain how to integrate the latest advances in medical, radiological, and surgical options for patients with malignancies into clinical practice
• Describe current and emerging molecularly targeted agents including their development and utility in cancer management
• Identify the rationale for the development of new cancer treatments based on underlying molecular mechanisms
• Review the latest advances in improving survival rates and quality of life for cancer patients

Statement of Educational Need
The National Cancer Institute estimates that approximately 10.5 million Americans with a history of cancer were alive in January 2003, and about 1.4 million new cases were expected to be diagnosed in 2008. With so many patients with cancer nationwide, there is tremendous variation in patterns of care. Despite national guidelines, such as National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO), surveys reflect that there are differences among community practices as well as basic awareness of new targeted agents and mechanisms of action for cancer treatment. Meanwhile, an increasing number of new therapeutic products are in clinical testing and going through the US Food and Drug Administration (FDA) approval process. It is critical that knowledge of new clinical information be disseminated to practicing oncologists as quickly as possible by experts in the field.

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and PRIME Oncology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 10.0 AMA PRA Category 1 Credits™ per activity. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care reccommendations.

Registration

Physicians Discounted . . . . . . . . . . . . . . . . . . . . . . . . . $250.00 Payment Received by February 23, 2009 Registration. . . . . . . . . . . . . . . . . . . . . . . . . $300.00 Payment received by March 27, 2009 Full/On-Site . . . . . . . . . . . . . . . . . . . . . . . . $350.00 Nurses/Students* Registration . . . . . . . . . . . . . . . . . . . . . . . .  $125.00 Payment received by March 27, 2009 Full/On-Site . . . . . . . . . . . . . . . . . . . . . . . . $175.00                                     *Proof of eligibility is required

Registration Includes

• Continental breakfast (Friday & Saturday)
• Lunch (Friday)
• Admission to all scientific sessions and conference materials
• CME certificate (upon request)
• Certificate of attendance

PRIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.


Register online at www.primeoncology.org/palmbeach. Registration closes on March 27, 2009. Attendees wishing to register after this date may register on-site. E-mail confirmation of your registration will be sent upon receipt of payment. PRIME Oncology reserves the right to alter activity titles, speakers, or sessions if circumstances so dictate and the right to cancel or reschedule this meeting due to unforeseen circumstances.


Cancellation/Substitutions Policy
A full refund, less an administrative fee of $25.00, will be given for cancellation notice in writing before March 20, 2009. No refunds will be given after this date. Substitutions will be accepted until March 27, 2009, with written notice.


Hotel Reservations
Hotel reservations must be made directly with the Westin Diplomat by calling 954 602 6000. Please advise that you are with the 11th Annual Palm Beach Cancer Symposium. The conference room rate is $286/night plus applicable taxes, currently at 11%. All reservations must be confirmed with a major credit card. Reservations must be made by March 10, 2009. After March 10, 2009, rooms will be provided on a space-available basis at the standard rate.


Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Susan Ahn by March 27, 2009, at 678 892 1340 or susan.ahn@primeoncology.org.